The Glymphatic System in α-Synucleinopathies Authors: Seong Ho Jeong, Seok Jong Chung, Phil Hyu Lee Published: 2026 ABSTRACT α-Synucleinopathies—including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)—are neurodegenerative disorders characterized by the pathological accumulation of misfolded α-synuclein. While current treatments remain largely symptomatic, emerging evidence suggests that impaired clearance of toxic proteins may underlie disease progression. The glymphatic system, a brain-wide network facilitating cerebrospinal fluid (CSF)-mediated waste removal through perivascular pathways and astrocytic aquaporin-4 (AQP4) channels, has gained attention as a key regulator of protein homeostasis in the central nervous system. This review synthesizes recent neuroimaging, pathological, and experimental data linking glymphatic dysfunction to α-synucleinopathies. Advanced MRI methods—including diffusion tensor imaging analysis along perivascular spaces (DTI-ALPS) and functional blood oxygen-level dependent-CSF coupling—reveal impaired glymphatic flow in PD, DLB, and MSA, with correlations to cognitive and motor decline. Animal and postmortem studies demonstrate that disruption of AQP4 polarization exacerbates α-synuclein accumulation and neurodegeneration. Furthermore, reduced glymphatic clearance may promote neuroinflammation and disease spread. These findings highlight the glymphatic system as a potentially modifiable contributor to α-synucleinopathy pathogenesis. Therapeutic strategies to enhance glymphatic clearance—including sleep optimization, pharmacologic modulation of AQP4, and novel device-based approaches—are under active investigation. Targeting the brain’s waste-clearance infrastructure may offer a new disease-modifying avenue in the treatment of α-synucleinopathies. INTRODUCTION α-Synucleinopathies—a group of neurodegenerative disorders including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)—are pathologically defined by the accumulation of misfolded α-synuclein protein in the brain.1 The excessive buildup of neurotoxic α-synuclein is central to their pathogenesis, driving neuronal dysfunction and cell death. However, current treatments are largely symptomatic, and disease-modifying strategies that clear or reduce α-synuclein pathology remain an urgent unmet need. In this context, the glymphatic system has emerged as a critical brain-wide clearance network that may help remove pathogenic proteins. The glymphatic system—a term combining “glial” and “lymphatic”—was only recently described as a mechanism for cerebrospinal fluid (CSF)-mediated waste clearance in the central nervous system.2 While the glymphatic system has been extensively studied for its role in clearing amyloid-β (Aβ), emerging evidence suggests it may also play a critical role in the clearance of extracellular α-synuclein.34 This review will provide an overview of the glymphatic system anatomy and physiology and synthesize emerging evidence of glymphatic dysfunction in PD, DLB, and MSA. We also discuss neuroimaging markers (such as diffusion tensor imaging analysis along perivascular spaces, DTI-ALPS) and experimental findings that link glymphatic failure to clinical features. Finally, therapeutic implications and future directions are highlighted, underscoring the potential of targeting the glymphatic-lymphatic clearance pathways in combating α-synucleinopathies. Overview of the glymphatic system (anatomy and physiology) The glymphatic system is a specialized fluid-clearance pathway in the brain, first described by Maiken Nedergaard’s team in 2012–2013.2 In this pathway, CSF flows along periarterial spaces into the brain parenchyma, where it mixes with interstitial fluid (ISF) to collect waste products. It then drains along perivenous spaces back into the surrounding CSF compartments. The term “glymphatic system” was coined to reflect its dependence on glial (astrocytic) aquaporin-4 (AQP4) water channels and its fluid and waste transport function analogous to the peripheral lymphatic system. The pathway of glymphatic system The glymphatic system follows a stepwise process for the clearance of waste products from the brain. First, arterial perivascular influx occurs as CSF from the subarachnoid space enters the brain along the periarterial spaces that surround cerebral arteries. These spaces serve as conduits for CSF, and the rhythmic pulsation of arterial walls with each heartbeat provides the mechanical force that pushes CSF inward into the brain tissue. This pumping effect is a critical initial driver of glymphatic flow. Once CSF has entered these perivascular routes, it undergoes parenchymal diffusion into the brain tissue. The fluid spreads through the narrow gaps between the endfeet of astrocytes—specialized glial cells that form the interface between blood vessels and neurons. These astrocytic endfeet are rich in AQP4 water channels, which are highly polarized and concentrated around blood vessels. These channels are essential for efficient fluid movement. Without them, the exchange between CSF and ISF is significantly impaired. Indeed, studies in AQP4-knockout mice have shown that deletion of these channels results in decreased glymphatic flow and reduced clearance of both Aβ and α-synuclein from the brain.24 Next, mixing with ISF and waste clearance occurs. As CSF disperses into the brain parenchyma, it combines with the existing ISF, allowing for the removal of solutes and metabolic byproducts. This process is driven by both convective bulk flow and passive diffusion. Larger molecules, including various waste products, are transported more effectively by bulk flow along structured pathways such as perivascular channels or white matter tracts. In contrast, smaller solutes tend to diffuse passively through the surrounding extracellular space. During this stage, metabolic waste products—such as Aβ, tau protein, and lactate—are collected by the CSF for clearance. Finally, perivenous drainage transports this waste-laden fluid out of the brain. The CSF–ISF mixture flows along perivenous spaces that surround cerebral veins. This includes pathways around deep penetrating white-matter veins and major draining veins. These drainage routes ultimately converge in the subarachnoid space near venous structures such as the basal cisterns and the dural venous sinuses. This perivenous route is considered the primary channel through which metabolic waste exits the brain into the broader CSF circulation. Then, the CSF containing waste is absorbed by meningeal lymphatic vessels—recently characterized channels located within the dura mater that connect to deep cervical lymph nodes (Fig. 1). Some portion of the CSF may also be absorbed directly into the venous blood through arachnoid granulations. Additionally, CSF can exit the brain along perineural spaces surrounding cranial and spinal nerves, ultimately connecting to peripheral lymphatic vessels. Together, these peripheral pathways act as secondary clearance routes, ensuring that metabolic waste products are removed from the central nervous system and returned to the systemic circulation for elimination from the body. AQP4 polarization and role In the glymphatic system, the polarized distribution of AQP4 water channels on astrocyte endfeet is a critical factor enabling fluid exchange in the brain parenchyma. Astrocyte processes (endfeet) envelop the interstitial spaces around brain microvessels and neurons; in particular, they form tight perivascular endfeet that wrap around capillary walls. The cell membranes at these perivascular endfeet have a high density of the water channel protein AQP4—a phenomenon referred to as AQP4 polarization.5 Such anatomical polarization enables water and solutes from CSF that enter the perivascular space (PVS) to rapidly spread into the brain tissue. Early studies by Iliff, et al.2 demonstrated the importance of AQP4: knocking out AQP4 in mice reduced β-amyloid clearance from the brain by about 55% and markedly impaired CSF–ISF mixing, effectively stalling glymphatic function. Therefore, AQP4 is considered an essential mediator of glymphatic flow, and any dysfunction or alteration in its polarized localization can lead to glymphatic impairment. Indeed, in aged mouse models, loss of AQP4 polarization on astrocytes (accompanied by increased perivascular neuroinflammation) has been associated with reduced waste clearance efficiency.6 Likewise, disturbed AQP4 polarization has been observed in the brains of human Alzheimer’s disease (AD) patients.7 Perivascular space The glymphatic pathway primarily operates through the PVS–the anatomical spaces surrounding blood vessels. As arteries or veins penetrate the brain, tiny fluid-filled spaces form around them, acting as channels for ISF. In young, healthy brains, these PVS are extremely small and not visible on conventional MRI. However, with aging or vascular disease, they can enlarge, appearing on MRI as enlarged perivascular spaces (EPVS).89 PVS are often classified by location. For example, Type I EPVS occur around the lenticulostriate arteries in the basal ganglia; Type II EPVS are found around penetrating arterioles in the subcortical white matter (centrum semiovale); and Type III EPVS (less commonly observed) are in the midbrain region, among other areas. These EPVS show different disease associations: EPVS in the basal ganglia are strongly associated with hypertension, aging, and small vessel disease (e.g., lacunar infarcts), whereas EPVS in the centrum semiovale are linked to recurrent microbleeds and cerebral amyloid angiopathy, and are frequently seen in AD patients.89101112 Consequently, quantifying the number, size, or volume of EPVS on MRI—or visually rating them—has been explored as an indirect indicator of brain waste-clearance function and the progression of neurodegenerative diseases. Driving forces and regulation Several physiological factors are known to influence and regulate glymphatic flow. One of the most fundamental drivers is the continuous production of CSF by the choroid plexus (CP) within the brain’s ventricles. This steady production creates a constant outward pressure that establishes a baseline pressure gradient, which in turn promotes the flow of CSF into the subarachnoid space and facilitates its entry into the glymphatic pathway. Another critical mechanism is the pulsation of cerebral arteries. With each heartbeat, the arterial walls rhythmically expand and contract, which compresses and relaxes the PVS surrounding them. This mechanical action effectively pumps CSF into the brain parenchyma during systole and facilitates its redistribution during diastole. Iliff and colleagues2 confirmed this through two-photon microscopy studies, demonstrating that suppressing arterial pulsatility significantly reduces the influx of tracers into the interstitial space of the brain. In addition to cardiac-related forces, fluctuations associated with the respiratory cycle also play an important role. Changes in intrathoracic pressure during breathing cause oscillations in venous outflow and intracranial pressure. These pressure variations generate waves that travel through the CSF, enhancing its movement. Notably, MRI-based assessments of CSF velocity have shown that respiratory-driven pressure changes can have an even greater effect on CSF dynamics than cardiac pulsations, highlighting the importance of respiration in modulating glymphatic flow. Glymphatic circulation is also affected by neurogenic vasomotion. This refers to slow, rhythmic changes in the diameter of cerebral arterioles controlled by the autonomic nervous system. These low-frequency oscillations, which occur a few times per minute, produce subtle but significant pressure waves that help propel CSF through the PVS and support overall glymphatic activity. Lastly, the state of consciousness—specifically, whether an individual is asleep or awake—has a profound impact on glymphatic function. During sleep or under anesthesia, the volume of the interstitial space in the brain expands by more than 60% compared to the awake state. This expansion allows CSF to penetrate more deeply into brain tissue, significantly enhancing the clearance of metabolic waste. Xie, et al.13 found that this waste removal process during sleep occurs at more than twice the rate observed during wakefulness. The underlying mechanism appears to involve a reduction in sympathetic nervous system activity during sleep, which leads to decreased levels of norepinephrine. Since norepinephrine maintains extracellular space contraction while awake, its suppression allows the interstitial space to relax and expand, facilitating glymphatic transport. In summary, glymphatic flow is strongly enhanced during sleep and significantly diminished during wakefulness due to these physiological shifts. Diffusion vs. convection debate It remains debated how much convective bulk flow contributes to waste transport in the glymphatic pathway versus how much is simply due to diffusion. Nedergaard’s group has argued for the presence of a significant bulk flow component, citing observations that relatively large molecules can move quickly over relatively long distances in the brain.214 On the other hand, Smith and colleagues15 have contended that such large-scale fluid movement is unlikely to be sustained in brain tissue under normal conditions and might be an artifact of experimental methods, positing that diffusion is the primary mechanism at work. The current prevailing view is a compromise: both convection and diffusion occur, with their relative contributions depending on factors like molecule size and specific anatomical pathways involved.16 Another aspect of debate is the directionality of glymphatic flow. The classical glymphatic model describes CSF moving from periarterial spaces into the parenchyma and then out via perivenous spaces (artery → brain → vein). However, some researchers have proposed an alternative or additional route known as intramural periarterial drainage, which involves waste flowing within the basement membranes of arterial walls. For instance, Albargothy, et al.17 observed β-amyloid moving along arterial basement membranes and argued that this intramural periarterial pathway might be the dominant route for clearance, rather than the glymphatic perivenous route. This issue of glymphatic vs. intramural arterial drainage is still an active topic of research and discussion in the field. EVIDENCE OF GLYMPHATIC DYSFUNCTION IN PD, DLB, AND MSA Parkinson’s disease Neuroimaging studies There is growing evidence that glymphatic clearance is impaired in PD. A number of MRI-based approaches have been developed to assess glymphatic function in humans, the most widely used being the DTI-ALPS method.18 DTI-ALPS quantifies the diffusivity of water along white matter tracts perpendicular vs. parallel to ventriculofugal (perivascular) orientations, yielding an index that reflects glymphatic transport efficiency. In healthy individuals, the ALPS index is relatively high, indicating free water movement along perivascular (glymphatic) pathways. In PD patients, multiple studies have now shown a significant reduction in the ALPS index compared to age-matched controls. For example, recent studies reported that PD patients had lower ALPS indices and that these indices correlated negatively with disease severity (patients with more advanced motor symptoms had worse glymphatic indices).1920 Other longitudinal studies found that a lower baseline ALPS index was associated with faster motor and cognitive decline over time in PD.212223 These findings provide neuroimaging evidence that glymphatic system dysfunction is present in PD and may even track with disease progression. MRI-visible PVS, often called Virchow-Robin spaces, are another marker linked to glymphatic function. EPVS on T2-weighted MRI indicate chronic impairment of ISF drainage, as these spaces expand when clearance is insufficient. In PD, EPVS are commonly observed, especially in the basal ganglia. Quantitative studies have shown that a greater burden of EPVS in the basal ganglia is associated with cognitive impairment in PD. Park, et al.24 reported that patients with more basal ganglia EPVS experienced more rapid cognitive decline over time. Similarly, our previous study found that newly diagnosed PD patients with a high EPVS load in the basal ganglia had a poorer long-term motor outcome, suggesting that EPVS burden could predict faster progression of motor disability.25 Furthermore, another recent study from our group noted that regional EPVS burden in PD correlated not only with cognitive deficits but also with neuropsychiatric symptoms such as depression and apathy.26 These correlations reinforce the idea that impaired glymphatic clearance might contribute to both the motor and non-motor manifestations of PD. It is noteworthy that EPVS in different brain regions may have distinct clinical correlates: basal ganglia EPVS relate to small vessel arteriopathy and have been tied to PD outcomes, whereas centrum semiovale EPVS are more linked to amyloid angiopathy and cerebral amyloid load as seen in AD.89101112 In PD, basal ganglia EPVS are of particular interest since this region is a predilection site for α-synuclein pathology and also a watershed of glymphatic flow from deep brain structures.202425 In addition to structural markers such as the ALPS index and EPVS burden, functional MRI approaches have begun to shed light on the dynamic aspects of glymphatic activity. One such method involves assessing the coupling between global blood oxygen-level dependent (gBOLD) signals and CSF flow. Unlike DTI-ALPS, which is limited to structural diffusivity patterns, gBOLD–CSF coupling captures the physiological interaction between neural activity and CSF dynamics. Notably, this coupling has been shown to be associated with motor and cognitive impairment in patients with PD.2728 These findings suggest that reduced gBOLD–CSF coupling may reflect impaired glymphatic clearance and provide a functional biomarker of glymphatic dysfunction in PD. Another intriguing imaging observation in PD is the role of the CP. The CP not only produces CSF but is increasingly recognized as an immunological interface and a possible modulator of waste clearance.29 Our previous studies showed that CP enlargement in PD has been associated with worse clinical outcomes. One recent study found that CP size correlated with the loss of nigral dopaminergic neurons [as measured by dopamine transporter (DAT) PET] and greater motor severity.30 Another study reported that PD patients with larger CP volume tended to have poorer cognitive performance.31 These correlations hint that CP changes (perhaps due to chronic inflammation or compensatory overproduction of CSF) might reflect glymphatic insufficiency–the CP could be overworking to compensate for impaired clearance, or conversely its dysfunction could be contributing to impaired clearance. Either way, the CP might serve as an imaging biomarker and possibly a therapeutic target (e.g., controlling CSF production or modulating CP immune activity) in PD. Experimental and pathological evidence The relationship between PD and glymphatic function is further supported by preclinical studies. Zhang, et al.4 demonstrated that genetic deletion of AQP4 or pharmacological suppression of glymphatic activity (e.g., via acetazolamide-induced reduction in CSF production) impaired the clearance of α-synuclein and accelerated dopaminergic neuron loss in the substantia nigra. In contrast, enhancing glymphatic flow through AQP4 overexpression or interventions promoting sleep improved α-synuclein clearance and attenuated disease pathology. Building on these findings, Si, et al.32 further elucidated the mechanistic link between neuroinflammation and glymphatic dysfunction. They showed that inhibiting matrix metalloproteinase-9 in a PD mouse model prevented the depolarization of AQP4 from astrocytic endfeet, thereby preserving glymphatic function and reducing α-synuclein-related toxicity. Similarly, Morawska, et al.33 demonstrated that disruption of slow-wave sleep in α-synuclein-overexpressing mice led to impaired proteostasis and exacerbated α-synucleinopathy. Complementing these insights, Zou, et al.34 reported that blocking meningeal lymphatic drainage worsened α-synuclein pathology and neuroinflammation, underscoring the importance of intact lymphatic efflux for glymphatic integrity. Most recently, Lopes, et al.3 provided direct evidence that glymphatic dysfunction facilitates the propagation of α-synuclein in vivo. Their study revealed that AQP4 deficiency not only impairs α-synuclein clearance but also enhances its transneuronal spread, suggesting that an intact glymphatic system may act as a barrier against the prion-like dissemination of misfolded α-synuclein. These results significantly advance our understanding of how glymphatic disruption may contribute to disease progression in a PD model. In summary, several preclinical and imaging studies showed clear signs of glymphatic system dysfunction: imaging shows reduced CSF-ISF exchange and structural markers of impaired clearance (like enlarged PVS and CP changes), while experimental models confirm that reducing glymphatic flow worsens α-synuclein accumulation and neuron loss. These findings tie impaired waste disposal to the pathophysiology of PD and suggest that glymphatic dysfunction might be an early event that both reflects and facilitates disease progression. Dementia with Lewy bodies DLB is another α-synucleinopathy that appears to involve glymphatic impairment. DLB shares overlapping pathology with PD (cortical Lewy bodies composed of α-synuclein) but presents primarily with cognitive decline, often accompanied by hallucinations, fluctuating attention, and parkinsonian motor features.35 It is also closely related to PD dementia, and together these conditions form a spectrum of Lewy body disorders.36 Research specifically examining glymphatic function in DLB has been limited until recently, but a few key studies shed light on its role. Neuroimaging evidence Several recent studies have provided converging evidence of glymphatic dysfunction in DLB using DTI-ALPS. One study provided the first direct evidence of glymphatic dysfunction in DLB using the DTI-ALPS technique.37 In this study, 26 DLB patients were compared to healthy controls. The results showed that the mean ALPS index was significantly lower in the DLB group than in controls, indicating a reduction in glymphatic activity in DLB. In fact, the magnitude of ALPS index reduction in DLB was on the order of what had been seen in PD in other studies, suggesting that Lewy body pathology in general is associated with impaired ISF clearance. Importantly, the study also examined correlations between the glymphatic index and other disease markers. Within the DLB patients, a higher ALPS index (i.e. better glymphatic function) correlated with greater gray matter volume in certain brain regions (notably the left insula) on MRI, as well as with higher dopaminergic activity as measured by DAT scan. DAT availability is a marker of dopaminergic neuron integrity in the basal ganglia; DLB typically shows reduced DAT availability due to nigrostriatal degeneration. The positive correlation between ALPS index and DAT availability in DLB suggests that patients with more intact glymphatic clearance tend to have less severe dopaminergic loss. Additionally, the ALPS index correlated with regional brain volume, hinting that glymphatic health may support preservation of brain structure against atrophy in DLB. Liaskovik, et al.38 evaluated the ALPS index across a broader spectrum of neurodegenerative diseases, confirming that DLB patients exhibit significantly lower glymphatic indices compared to healthy individuals. Their results also reinforced the link between reduced glymphatic activity and structural brain changes in DLB. More recent work by Firbank, et al.39 provided more granular insight into glymphatic dysfunction in Lewy body disease. The study included 32 patients with DLB, 31 with mild cognitive impairment with Lewy bodies (MCI-LB), and matched comparator groups including AD, MCI-AD, and healthy controls (n=48). The results demonstrated that DTI-ALPS indices were significantly reduced in both DLB and MCI-LB groups compared to healthy controls, with the strongest reductions seen in the DLB cohort. This supports the presence of glymphatic impairment even in prodromal Lewy body disease. Importantly, the ALPS index showed both cross-sectional and longitudinal associations with cognitive performance: lower ALPS values were linked to worse baseline cognitive scores as well as faster cognitive decline over time. In addition, DTI-ALPS was significantly associated with plasma biomarkers of neurodegeneration—specifically, higher levels of neurofilament light chain and glial fibrillary acidic protein—but showed no significant relationship with amyloid PET uptake or plasma Aβ. This dissociation suggests that glymphatic dysfunction in DLB may be more closely related to axonal injury and astroglial activation than to amyloid pathology. Experimental evidence Direct experimental models of DLB per se are scarce, since animal models typically mimic PD or PD dementia. However, concepts derived from PD models likely apply. For instance, if AQP4 polarization is disrupted in PD cortex,40 one might expect a similar or greater disruption in DLB cortex given the heavier burden of cortical Lewy bodies. Furthermore, AD pathology commonly coexists with DLB,41 and AD is firmly linked to glymphatic failure–amyloid plaques accumulate when glymphatic clearance of Aβ falters.42 It has been hypothesized that glymphatic failure could be a unifying mechanism that synergistically exacerbates multiple pathologies: in DLB, impaired clearance might allow both α-synuclein and amyloid/tau to build up, thereby driving a particularly aggressive cognitive decline. In summary, emerging data indicate that DLB, like PD, exhibits glymphatic system dysfunction. DTI-ALPS imaging demonstrates reduced glymphatic flow in DLB patients, correlating with brain atrophy and dopaminergic loss. While experimental evidence is indirectly drawn from related models, it strongly suggests that failing glymphatic clearance of α-synuclein (and co-pathogens such as amyloid) contributes to the disease process in DLB. These findings open the door for using glymphatic imaging in the evaluation of DLB and even raise the possibility of glymphatic-enhancing interventions as part of future therapy for Lewy body dementias. Multiple system atrophy MSA is an atypical parkinsonian disorder and α-synucleinopathy characterized by glial cytoplasmic inclusions of α-synuclein (primarily in oligodendrocytes), and clinically by a combination of parkinsonism, cerebellar ataxia, and autonomic failure. MSA is a rarer condition but often more rapidly progressive than PD or DLB. Given the distinct glial focus of α-synuclein in MSA, it is valuable to investigate whether glymphatic impairment is also a feature, and indeed recent evidence indicates it is. Neuroimaging evidence One recent study applied an advanced diffusion MRI method to assess glymphatic clearance in MSA.43 This study used diffusion spectrum imaging—an approach related to DTI but capable of resolving more complex diffusion patterns—in combination with the ALPS index analysis. The cohort included 44 MSA patients (11 MSA-P subtype with predominant parkinsonism, and 33 MSA-C subtype with predominant cerebellar features) and 30 healthy controls. MSA patients had significantly lower ALPS indices compared to controls (mean ~1.46 in MSA vs. 1.63 in controls). This indicates a clear reduction in glymphatic ISF transport in MSA. Both the parkinsonian and cerebellar subgroups of MSA showed similarly reduced ALPS index values (no significant difference between MSA-P and MSA-C), suggesting that glymphatic dysfunction is a general phenomenon in MSA, not tied to whether parkinsonian or cerebellar symptoms dominate. In this study, no significant correlation was found between the ALPS index and clinical disability scores (Unified MSA Rating Scale). This lack of correlation could be due to several reasons: it might mean that glymphatic dysfunction reaches a plateau or threshold early in the disease (thus even patients with milder MSA already have a markedly impaired ALPS index, leaving little dynamic range to correlate with further severity). It could also reflect limitations of current clinical scales or imaging sensitivity. Nonetheless, the fundamental takeaway is that MSA, like PD and DLB, shows objective evidence of impaired glymphatic clearance on imaging. Experimental/pathological evidence Specific studies on glymphatic clearance in MSA animal models are currently lacking, in part due to the limited availability of transgenic MSA models. However, the evidence from human imaging is compelling on its own. Recent postmortem research has offered important insights into underlying structural changes. Wang, et al.40 examined AQP4 distribution patterns in α-synucleinopathy subtypes, focusing on its perivascular localization—a critical component of glymphatic transport. Their analysis revealed that significant AQP4 depolarization was present specifically in the MSA-P subtype, with no comparable changes observed in MSA-C. These findings reinforce the concept that glymphatic impairment is not uniform across α-synucleinopathies but may vary by disease subtype and anatomical vulnerability. In the case of MSA-P, early astrocytic and vascular involvement in the putamen may contribute to regional glymphatic disruption, potentially accelerating α-synuclein aggregation and neurodegeneration. Further studies are needed to determine whether these AQP4 alterations represent a cause or consequence of MSA pathology and whether they can serve as a therapeutic target in select patient subtypes. In summary, although MSA has distinct pathological features compared to other α-synucleinopathies—most notably the oligodendroglial accumulation of α-synuclein—recent neuroimaging and postmortem data suggest that glymphatic dysfunction is also a prominent feature of the disease. Diffusion MRI studies have demonstrated significantly reduced ALPS indices in both MSA-P and MSA-C, indicating impaired ISF transport regardless of clinical subtype. Moreover, pathological findings of AQP4 depolarization selectively in MSA-P support a subtype-specific disruption of astrocytic water channel polarization, further implicating glymphatic failure in disease pathophysiology. Together, these findings highlight that glymphatic impairment is not only present in MSA but may vary in degree and distribution depending on regional vulnerability and underlying cellular pathology. Therapeutic implications and future directions As summarized in Table 1, extensive imaging and experimental evidence links glymphatic dysfunction to the pathogenesis of PD, DLB, and MSA. Given this growing body of evidence, a compelling new approach is to target the glymphatic system for therapeutic benefit. Enhancing the brain’s own waste-clearance pathways could, in theory, reduce the accumulation of α-synuclein and other neurotoxic species, thereby modifying disease progression. While this is a nascent area of translational research, several avenues—ranging from lifestyle modifications to pharmacological and device-based interventions—are being explored. Sleep enhancement Prioritizing and restoring slow-wave sleep is arguably the most practical and immediately impactful strategy to boost glymphatic clearance.13 Patients with PD, DLB, and MSA often have fragmented sleep and reduced deep sleep,444546 so interventions that improve sleep quality could enhance nightly glymphatic function. Sleep hygiene counseling (consistent sleep schedule, optimizing bedroom environment, avoiding caffeine/alcohol before bed) is a foundational step. Pharmacologically, melatonin is widely used in α-synucleinopathy patients, especially for REM sleep behavior disorder (RBD) and insomnia.47 Beyond its role in regulating circadian rhythms, melatonin may directly influence glymphatic flow: animal studies have hinted that melatonin can increase interstitial clearance, possibly via its sedative effects promoting deep sleep.4849 Clinically, several studies have shown that melatonin improved sleep efficiency in patients with PD.5051 Another approach is the use of orexin (hypocretin) antagonists (e.g., suvorexant), which promote sleep onset and maintenance and have recently shown efficacy in treating insomnia in PD.5253 By increasing time spent in slow-wave sleep, these agents could facilitate glymphatic waste removal each night. A special consideration is given to RBD, which often precedes α-synucleinopathies. Treating RBD with melatonin or clonazepam not only protects patients and their bed partners from injury but may also indirectly benefit brain health by reducing sleep fragmentation. Although clonazepam itself does not increase deep sleep (it mainly suppresses muscle activity during REM), ensuring that patients get adequate overall sleep in RBD could help maintain glymphatic clearance in the prodromal stages of disease. Additionally, recent evidence has shown that GABAA receptor activation enhances glymphatic clearance in an AQP4-dependent manner,54 which reinforces the use of clonazepam for treating RBD in patients with PD. In patients with obstructive sleep apnea (OSA)—a common comorbidity in midlife that is known to impair slow-wave sleep—aggressive management with continuous positive airway pressure (CPAP) could be beneficial. Intriguingly, a recent meta-analysis found evidence of glymphatic pathway dysfunction in patients with severe OSA,55 and one study reported that CPAP treatment increased CSF flow and glymphatic transport in OSA patients.56 Since OSA is a risk factor for cognitive decline and possibly PD, treating it might mitigate some glymphatic impairment, offering neuroprotection. Pharmacological targets AQP4 water channels on astrocytes are an attractive drug target for enhancing glymphatic clearance. If one could pharmacologically upregulate AQP4 expression or improve its polarized localization, it might accelerate ISF exchange. Some experimental small molecules and peptide drugs that enhance AQP4 channel activity have been proposed,57 but none are clinically available yet. An alternative strategy is to prevent the loss of AQP4 polarization. For example, blocking the cascade that leads to dystroglycan cleavage [such as using matrix metalloproteinase-9 (MMP-9) inhibitors] could preserve AQP4 anchoring on endfeet.32 There is ongoing research into MMP inhibitors or other neuroprotective agents that might incidentally support perivascular astrocytic endfeet integrity. Beyond AQP4, other molecular targets include modulators of arterial pulsatility and vasomotion. For instance, drugs that enhance vasomotor oscillations or improve endothelial function might promote glymphatic flow. One possible target is the noradrenergic system: excessive noradrenaline (as in stress or wakefulness) contracts interstitial space, so drugs that reduce locus coeruleus activity or antagonize adrenergic receptors in the brain during sleep might prolong the glymphatic-friendly environment.58 This is partly how sedatives like dexmedetomidine work–by mimicking the sleep state and activating the same neural circuits as deep sleep, they can increase glymphatic influx. In fact, low-dose nighttime infusions of dexmedetomidine are being tested in ICU patients to improve delirium and cognitive outcomes by harnessing this glymphatic stimulation principle.596061 Another potential pharmacologic avenue is the use of osmotic agents. High osmolarity drugs like mannitol or hypertonic saline, when administered systemically, can draw fluid out of the brain interstitium and potentially augment convective flow.262 Mannitol is sometimes used acutely to reduce intracranial pressure; chronically, a milder osmotic effect (e.g., a controlled mannitol oral solution) might theoretically promote glymphatic clearance. There is interest in whether such approaches could help clear protein aggregates, though care must be taken to avoid electrolyte imbalance. Device-based and stimulation therapies As our understanding of glymphatic physiology deepens, several device-based and stimulation-oriented strategies have emerged that aim to enhance glymphatic clearance and reduce toxic protein accumulation in neurodegenerative diseases, particularly AD. These non-pharmacologic approaches represent a novel therapeutic avenue with potential applicability to α-synucleinopathies as well. Photobiomodulation (PBM) has been proposed as one such strategy. Near-infrared light stimulation improved glymphatic flow and facilitated Aβ clearance in animal models of AD.63 Notably, the effectiveness of PBM varied depending on disease stage: early intervention promoted Aβ removal and reduced neuroinflammation, whereas late-stage stimulation was less effective, underscoring the importance of timing. These findings suggest that phototherapy may modulate cerebrovascular tone and astrocyte function to enhance ISF exchange. Another novel approach is gamma-frequency (40 Hz) sensory stimulation. Murdock, et al.64 reported that 40-Hz multisensory (visual and auditory) stimulation significantly boosted glymphatic clearance of Aβ in AD mouse models. This treatment appeared to promote neural entrainment, improve vascular pulsatility, and restore perivascular AQP4 localization. Importantly, glymphatic enhancement was accompanied by cognitive improvements, suggesting a functional impact of this technique. Though the study focused on amyloid pathology, the potential for similar mechanisms to enhance α-synuclein clearance in α-synucleinopathies remains to be explored. Focused ultrasound (FUS) combined with intravenously administered microbubbles has also shown promise. Ye, et al.65 demonstrated that this technique can mechanically stimulate glymphatic transport by transiently opening PVS, thereby accelerating solute clearance. In AD models, FUS-enhanced glymphatic flow led to a significant reduction in Aβ burden without inducing overt tissue damage. This strategy holds translational potential for targeted, region-specific modulation of glymphatic function in vivo. Lifestyle and vascular risk factor management General cardiovascular health measures likely support glymphatic function. Regular aerobic exercise has been associated with improved cognition in PD and DLB patients.6667 Exercise can increase cerebral blood flow, promote angiogenesis, and improve sleep quality–all factors that would secondarily enhance glymphatic circulation.68 In mouse models, exercise was shown to elevate the expression of AQP4 and improve the clearance of Aβ from the brain, suggesting a direct upregulation of glymphatic pathways.69 Additionally, managing vascular risk factors (blood pressure, cholesterol, diabetes) is important.70 Chronic hypertension, for instance, stiffens arteries and reduces their pulsatility, which is detrimental to glymphatic pumping. By controlling blood pressure, arterial elasticity is better preserved, thus maintaining the driving forces for CSF–ISF exchange. There is also evidence that midlife hypertension and diabetes correlate with lower DTI-ALPS indices in later life, linking systemic health to glymphatic health.717273 Therefore, aggressive management of vascular comorbidities in patients with prodromal PD/DLB (or those at risk, such as idiopathic RBD patients) might delay glymphatic decline and neurodegeneration. CONCLUSION Emerging evidence from both preclinical studies and human neuroimaging has increasingly implicated the glymphatic system in the pathophysiology of α-synucleinopathies, including PD, DLB, and MSA. Across all three disorders, structural and functional markers—such as reduced ALPS indices, EPVS, CP abnormalities, and impaired gBOLD–CSF coupling—support the presence of glymphatic dysfunction. Experimental data reinforce these findings, showing that disruption of glymphatic pathways accelerates α-synuclein aggregation and neurodegeneration, while restoration of glymphatic function can mitigate disease progression. Importantly, glymphatic failure may not only contribute to protein accumulation but also interact with neuroinflammatory and vascular processes, potentially forming a feed-forward loop that amplifies neurodegeneration. The detection of glymphatic impairment in early and prodromal stages (e.g., MCI-LB, idiopathic RBD) opens opportunities for early diagnosis and intervention. Moreover, therapeutic strategies aimed at enhancing glymphatic clearance—such as sleep optimization, pharmacological targeting of AQP4 and vasomotion, and device-based approaches like PBM or FUS—represent a promising new direction for disease-modifying therapies. Future research should aim to establish and validate glymphatic biomarkers across the spectrum of α-synucleinopathies and determine their prognostic and therapeutic relevance. Clarifying the causal role of glymphatic dysfunction in α-synuclein accumulation and neurodegeneration will be essential. Moreover, clinical trials should evaluate whether enhancing glymphatic clearance—via sleep optimization, AQP4 modulation, or device-based stimulation—can modify the disease course. As our understanding of glymphatic physiology advances, targeting brain clearance mechanisms may represent a transformative strategy for slowing or halting α-synucleinopathy progression.